Share on StockTwits

Investment analysts at Stifel Nicolaus assumed coverage on shares of BIND Therapeutics (NASDAQ:BIND) in a note issued to investors on Tuesday. The firm set a “buy” rating and a $20.00 price target on the stock. Stifel Nicolaus’ target price indicates a potential upside of 115.75% from the stock’s previous close.

BIND Therapeutics (NASDAQ:BIND) opened at 9.27 on Tuesday. BIND Therapeutics has a one year low of $8.00 and a one year high of $15.89. The stock has a 50-day moving average of $10.06 and a 200-day moving average of $10.79. The company’s market cap is $153.3 million.

BIND Therapeutics (NASDAQ:BIND) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.51) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.60) by $0.09. The company had revenue of $2.46 million for the quarter, compared to the consensus estimate of $2.20 million. Analysts expect that BIND Therapeutics will post $-2.06 EPS for the current fiscal year.

Separately, analysts at Credit Suisse reiterated an “outperform” rating on shares of BIND Therapeutics in a research note on Thursday, July 3rd. They now have a $20.00 price target on the stock, down previously from $21.00.

BIND Therapeutics Inc is a clinical-stage nanomedicine platform company developing Accurins, its targeted and programmable therapeutics.

Receive News & Ratings for BIND Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIND Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.